TAKE16.78

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹248 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity1,348.13182.5335.0035.00
Return on Assets-135.77102.7129.9429.94
Return on Capital Employed2,029.37-36.64-6.20-6.20
Return on Invested Capital-117.05-43.82-6.03-5.50
Margins
EBITDA Margin-20.54-3.53-2.05
Operating Margin-32.54-3.55-3.55
Incremental Operating Margin-21.0810.33
Pretax Margin-180.458.157.17
Net Income Margin-182.3320.0215.16
Net Income to Common Margin-182.33
FCF Margin2.13-7.61-7.61
Additional
Effective Tax Rate-1.040.003.622.64
Dvd Payout Ratio-0.060.100.00
Sustainable Growth Rate1,348.95182.3435.0035.00
Incremental Operating Margin %-21.0810.330.61
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.